Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.
about
Concise review: programming human pluripotent stem cells into bloodSkeletal stem cellsPluripotent stem cells in research and treatment of hemoglobinopathiesHematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells.Dendritic cells derived from pluripotent stem cells: Potential of large scale productionDisease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe applicationImproving the outcome of leukemia by natural killer cell-based immunotherapeutic strategiesExperimental approaches to derive CD34+ progenitors from human and nonhuman primate embryonic stem cellsThe RUNX1 +24 enhancer and P1 promoter identify a unique subpopulation of hematopoietic progenitor cells derived from human pluripotent stem cellsDefinitive Hematopoietic Multipotent Progenitor Cells Are Transiently Generated From Hemogenic Endothelial Cells in Human Pluripotent Stem Cells.Understanding of molecular mechanisms in natural killer cell therapyNK cells in therapy of cancerLent-On-Plus Lentiviral vectors for conditional expression in human stem cellsSpecific marking of hESCs-derived hematopoietic lineage by WAS-promoter driven lentiviral vectorsHuman definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages.Engineering the haemogenic niche mitigates endogenous inhibitory signals and controls pluripotent stem cell-derived blood emergence.NK cell-based immunotherapy for malignant diseases.Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsNatural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveSignalling pathways that control vertebrate haematopoietic stem cell specification.Amyotrophic lateral sclerosis - cell based therapy and novel therapeutic development.Unique differentiation profile of mouse embryonic stem cells in rotary and stirred tank bioreactors.Induction of adult levels of β-globin in human erythroid cells that intrinsically express embryonic or fetal globin by transduction with KLF1 and BCL11A-XLTherapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models.Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting.Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.Macrophages prevent human red blood cell reconstitution in immunodeficient mice.Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.Highly potent human hematopoietic stem cells first emerge in the intraembryonic aorta-gonad-mesonephros region.Maturing reticulocytes internalize plasma membrane in glycophorin A-containing vesicles that fuse with autophagosomes before exocytosis.Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point MutationPluripotent stem cell applications for regenerative medicineEngineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.Enforced Expression of HOXB4 in Human Embryonic Stem Cells Enhances the Production of Hematopoietic Progenitors but Has No Effect on the Maturation of Red Blood Cells.miR-451 Up-regulation, Induce Erythroid Differentiation of CD133+cells Independent of Cytokine Cocktails.Gene Correction of iPSCs from a Wiskott-Aldrich Syndrome Patient Normalizes the Lymphoid Developmental and Functional Defects.Endothelial reconstitution by CD34+ progenitors derived from baboon embryonic stem cells.A synthetic three-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells.Identification of the niche and phenotype of the first human hematopoietic stem cells.Red blood cells from pluripotent stem cells for use in transfusion.
P2860
Q26753182-49898950-8704-405E-A48C-6F1252A4A3DAQ26823973-2F12876D-B120-4A0A-9C72-66D250E1D1C4Q26825713-5F25A445-D66D-42D8-AD78-2BEE3766C79BQ26851475-BB612DDC-F845-48F3-AFBC-BC8F66CF53DEQ26865622-8E67A9FA-737C-47DE-9B47-C614DF828193Q26866409-E80DBEA6-2A32-44CA-9F37-94CB1369D95BQ26996660-9237643C-52F1-4AA0-91B4-77151628F10FQ27026573-89BB48E5-0669-4476-9592-960CF70CBCA4Q27329605-EA42F75B-F7CD-4E14-8A2C-116F21F4A9BFQ27334325-BAAAD26C-BF21-4F7E-83FD-F52BD0FC7A7AQ28086976-57853B53-A824-4D69-B09E-C17834FE5C82Q28242241-7C807AED-67A7-45E3-B3FF-EDA74AEAF4AEQ28595666-D8508A7C-54C2-4580-9824-D21181FA8AF1Q28728465-3DE8C802-59E3-4880-AB3E-48207A1CB05AQ30662761-31563E93-DB54-4268-9E94-CC5A9ABF7BEEQ33815740-EA30DE24-292A-4F7C-8940-37FDD42DC4D2Q33827433-5B73CF26-3AAF-4C9C-807F-DDE15F22B4C5Q33894805-A09B17ED-AA88-4914-B004-133F0BF2EC7DQ34180695-B073FA3D-5EEB-470E-A9F8-04A2679A874CQ34213551-225A5E4E-8F55-4BA9-9518-66F2CEA483D7Q34241565-CF6B2064-AC16-4C1E-A051-28C1D44E805FQ34246498-5C7D4810-CE0B-4A60-B09F-F4ACEFA470C4Q34463668-E056B2AB-4110-4434-A11F-348E499133A1Q34797365-06511466-ABE6-4A93-86F3-FDB9C97C3FD2Q35030912-B9EB75DE-1E40-4611-8BD7-ECA551AE2929Q35525329-FE23E76C-6743-4401-A669-511DADBF5DAEQ35585979-0712C366-D775-4ED6-9662-51B89262723FQ35588890-86FD6721-54D2-4DEC-A432-B6BE39B8B326Q35669117-7D1EAC4F-2BDF-4B52-99A1-B012CC0E8225Q36058548-31BFE3A4-7824-4A1D-8965-8BF9823206B0Q36236565-CAF0D6BD-83D5-4F12-8CF2-9EC47CF40917Q36255019-371802F8-AD67-4BAD-BDC8-AA937DCA68DDQ36936632-BCF7085D-83AD-4015-9408-8EF1BE7C5315Q37111916-3C0135CE-D0E6-4CAE-9E2D-4BA3DF8D5F99Q37134268-E37D0E35-4F7C-4DE6-93C2-A05BF5A6A31AQ37171312-E60FE291-E4E0-4F2C-9BEE-441059BF1F65Q37270232-7EA542C7-08C9-43D3-95ED-B9BADB4133C5Q37299126-B1C6295C-EEF4-485A-812C-D5FF843895AEQ37702474-89D8F711-F1EE-4E3B-840C-8C7A3442ADA5Q37747344-DA1AE738-AA6B-4C03-9D84-87DA26CC3905
P2860
Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Toward clinical therapies usin ...... human pluripotent stem cells.
@en
Toward clinical therapies usin ...... human pluripotent stem cells.
@nl
type
label
Toward clinical therapies usin ...... human pluripotent stem cells.
@en
Toward clinical therapies usin ...... human pluripotent stem cells.
@nl
prefLabel
Toward clinical therapies usin ...... human pluripotent stem cells.
@en
Toward clinical therapies usin ...... human pluripotent stem cells.
@nl
P2860
P1433
P1476
Toward clinical therapies usin ...... m human pluripotent stem cells
@en
P2093
Dan S Kaufman
P2860
P304
P356
10.1182/BLOOD-2009-03-191304
P407
P577
2009-08-03T00:00:00Z